Published • loading... • Updated
A cancer vaccine is closer than ever
Jarvis says recent scientific advances have made a personalized vaccine approach closer to reality, with researchers still testing how well it works.
- Merck & Co. and Moderna Inc. are moving cancer vaccine research beyond the "hope" and "promise" phases, Bloomberg columnist Jarvis writes, developing personalized treatments to help the immune system identify and destroy cancer cells.
- By sequencing a patient's tumor, scientists identify specific mutations and create personalized mRNA strands that teach the immune system to recognize these mutations and destroy cancer cells.
- Michael Postow of Memorial Sloan Kettering noted that adding the vaccine to Keytruda is a "quite big achievement," as the combination has shown success in preventing recurrence.
- Researchers are now shifting focus toward starting immunotherapy before surgery to keep the disease at bay, aiming to help the immune system recognize and destroy cancer cells more effectively.
- Despite promising early findings, developers must still convince medical science skeptics that these vaccines work, as ongoing research aims to prove effectiveness against difficult tumors like pancreatic cancer.
Insights by Ground AI
13 Articles
13 Articles
Coverage Details
Total News Sources13
Leaning Left2Leaning Right1Center10Last UpdatedBias Distribution77% Center
Bias Distribution
- 77% of the sources are Center
77% Center
15%
C 77%
Factuality
To view factuality data please Upgrade to Premium
